Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander‐Tetri, Rohit Seth Loomba, Arun Jayant Sanyal et al. · The Lancet · 2014
Cited by 2,228 works. doi:10.1016/s0140-6736(14)61933-4
Authors
- Brent A. Neuschwander‐Tetri
- Rohit Seth Loomba
- Arun Jayant Sanyal
- Joel E. Lavine
- Mark L. Van Natta
- Manal F. Abdelmalek
- Naga Chalasani
- Srinivasan Dasarathy
- Anna Mae Diehl
- Bilal Hameed
- Kris V. Kowdley
- Arthur J. McCullough
- Norah A. Terrault
- Jeanne M. Clark
- James Tonascia
- Elizabeth M. Brunt
- David Erwin Kleiner
- Edward C. Doo
References
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ
- NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- Pleiotropic Roles of Bile Acids in Metabolism
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease